Thermo Fisher Scientific Inc. (NYSE:TMO) is Shufro Rose & Co. LLC’s 5th Largest Position

Shufro Rose & Co. LLC decreased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating) by 4.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 69,292 shares of the medical research company’s stock after selling 2,899 shares during the quarter. Thermo Fisher Scientific makes up about 3.2% of Shufro Rose & Co. LLC’s holdings, making the stock its 5th biggest position. Shufro Rose & Co. LLC’s holdings in Thermo Fisher Scientific were worth $40,927,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. BlackRock Inc. grew its stake in Thermo Fisher Scientific by 3.8% in the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock valued at $20,672,838,000 after buying an additional 1,143,333 shares during the last quarter. State Street Corp grew its stake in Thermo Fisher Scientific by 3.4% in the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock valued at $10,828,875,000 after buying an additional 529,712 shares during the last quarter. Capital Research Global Investors grew its stake in Thermo Fisher Scientific by 2.3% in the 4th quarter. Capital Research Global Investors now owns 9,454,032 shares of the medical research company’s stock valued at $6,308,097,000 after buying an additional 208,075 shares during the last quarter. Geode Capital Management LLC grew its stake in Thermo Fisher Scientific by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 6,403,805 shares of the medical research company’s stock valued at $4,261,136,000 after buying an additional 214,375 shares during the last quarter. Finally, Norges Bank acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $2,784,029,000. Institutional investors and hedge funds own 87.48% of the company’s stock.

Insider Buying and Selling

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 13,030 shares of the company’s stock in a transaction that occurred on Friday, May 27th. The shares were sold at an average price of $565.04, for a total value of $7,362,471.20. Following the completion of the sale, the chief operating officer now owns 15,758 shares of the company’s stock, valued at $8,903,900.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, COO Michel Lagarde sold 13,030 shares of the stock in a transaction on Friday, May 27th. The shares were sold at an average price of $565.04, for a total transaction of $7,362,471.20. Following the completion of the sale, the chief operating officer now owns 15,758 shares of the company’s stock, valued at $8,903,900.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $588.36, for a total transaction of $5,883,600.00. Following the transaction, the chief executive officer now owns 183,373 shares of the company’s stock, valued at approximately $107,889,338.28. The disclosure for this sale can be found here. Insiders sold a total of 40,994 shares of company stock valued at $23,135,570 over the last ninety days. Insiders own 0.43% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of research analyst reports. Wells Fargo & Company lowered shares of Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $605.00 to $525.00 in a research note on Monday, April 25th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $630.00 to $685.00 and gave the stock an “overweight” rating in a report on Monday. SVB Leerink raised their price objective on shares of Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. Finally, Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $670.00 to $678.00 and gave the company an “overweight” rating in a report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $661.08.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $3.40 during trading hours on Friday, reaching $586.60. 42,643 shares of the company were exchanged, compared to its average volume of 1,471,714. Thermo Fisher Scientific Inc. has a fifty-two week low of $497.83 and a fifty-two week high of $672.34. The stock’s fifty day moving average is $548.67 and its two-hundred day moving average is $557.79. The company has a market cap of $229.63 billion, a price-to-earnings ratio of 31.40, a P/E/G ratio of 1.83 and a beta of 0.83. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.65 and a quick ratio of 1.13.

Thermo Fisher Scientific (NYSE:TMOGet Rating) last announced its earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.92 by $0.59. The company had revenue of $10.97 billion for the quarter, compared to analyst estimates of $9.95 billion. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. Thermo Fisher Scientific’s quarterly revenue was up 18.3% on a year-over-year basis. During the same period in the prior year, the business earned $5.60 earnings per share. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 14th. Investors of record on Thursday, September 15th will be paid a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a dividend yield of 0.20%. The ex-dividend date is Wednesday, September 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 6.39%.

About Thermo Fisher Scientific

(Get Rating)

Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Featured Stories

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMOGet Rating).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.